DUOMO HP

This brand name is authorized in Brazil, Ecuador

Active ingredients

The drug DUOMO HP contains a combination of these active pharmaceutical ingredients (APIs):

1 Doxazosin
UNII 86P6PQK0MU - DOXAZOSIN MESYLATE

Doxazosin is a potent and selective post-junctional alpha-1-adrenoceptor antagonist. This action results in a decrease in systemic blood pressure.

Read about Doxazosin
2 Finasteride
UNII 57GNO57U7G - FINASTERIDE

Finasteride is a competitive inhibitor of human 5α-reductase, an intracellular enzyme which metabolises testosterone into the more potent androgen, dihydrotestosterone (DHT). In benign prostatic hyperplasia (BPH), enlargement of the prostate gland is dependent upon the conversion of testosterone to DHT within the prostate. Finasteride is highly effective in reducing circulating and intraprostatic DHT. Finasteride has no affinity for the androgen receptor.

Read about Finasteride

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
G04CX Other drugs used in benign prostatic hypertrophy G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy
Discover more medicines within G04CX

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 508013050096805, 508013080098703, 508018090122603
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 1423-MEE-0915

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈